表紙
市場調查報告書

特發性肺纖維化(IPF)- 流行病學預測 2030年

Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 534893
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
特發性肺纖維化(IPF)- 流行病學預測 2030年 Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030
出版日期: 2020年02月01日內容資訊: 英文 110 Pages
簡介

特發性肺纖維化(IPF)是稀少的慢性進行性纖維化間質性肺病變,已知會影響中老年人。並且,隨時間不可逆性地間質變厚,給予肺組織,尤其是肺泡影響。還有血液中的含氧量受限制,走路和日常生活上會覺得呼吸急促。主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的特發性肺纖維化(IPF)的總患病數2017年估計為22萬9,170人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙)的特發性肺纖維化(IPF)市場調查,市場及疾病概要,整體及各國流行病學的預測,各重病度、性別、年齡層的患病數的變化與預測,未滿足需求,現行的治療方法等相關資訊 彙整。

目錄

第1章 重要的洞察

第2章 特發性肺纖維化(IPF)市場概要

  • 市場佔有率與分佈(成果值)
  • 市場佔有率與分佈(預測值)

第3章 疾病的背景和概要:特發性肺纖維化(IPF)

  • 簡介
  • 特發性肺纖維化(IPF)相關統計
  • 特發性肺纖維化(IPF)的病期分類
  • 危險因素和原因
  • 症狀
  • 病因
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的特發性肺纖維化(IPF)的患病數

第5章 特發性肺纖維化(IPF)的流行病學:各國

  • 美國
    • 特發性肺纖維化(IPF)的患病數
    • 特發性肺纖維化(IPF)的患病數:各重症度
    • 特發性肺纖維化(IPF)的患病數:性別
    • 特發性肺纖維化(IPF)的患病數:各年齡層
  • 歐洲5個國家
    • 特發性肺纖維化(IPF)的患病數
    • 德國
    • 法國
    • 義大利
    • 英國
    • 西班牙
  • 日本
    • 特發性肺纖維化(IPF)的患病數

第6章 現行的治療方法

  • ATS/ERS/JRS/ALAT臨床診療指南:特發性肺纖維化(IPF)的治療(2011臨床診療指南的更新)
  • peishentojani

第7章 未滿足需求

第8章 附錄

  • 調查方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0117

DelveInsight's 'Idiopathic Pulmonary Fibrosis (IPF)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Idiopathic Pulmonary Fibrosis Disease Understanding

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as 'Diffuse Parenchymal Lung Diseases,' which is characterized by a broader umbrella of 'Interstitial Lung Diseases (IDLs).

Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Idiopathic Pulmonary Fibrosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017.

Report Scope

  • The report covers detailed overview of Idiopathic Pulmonary Fibrosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Idiopathic Pulmonary Fibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of Idiopathic Pulmonary Fibrosis in 7MM

Key strengths

  • 11 Year Forecast of Idiopathic Pulmonary Fibrosis epidemiology
  • 7MM Coverage
  • Total prevalent cases of IPF
  • Incident Cases according to segmentation: Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017
  • 2.2. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2028

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

  • 3.1. Introduction
  • 3.2. Statistics about Idiopathic Pulmonary Fibrosis
  • 3.3. Staging of Idiopathic Pulmonary Fibrosis
  • 3.4. Risk Factors and Disease Causes
  • 3.5. Symptoms
  • 3.6. Pathogenesis
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis

5. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis

  • 5.1. United States
    • 5.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
    • 5.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
    • 5.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
  • 5.2. EU5
    • 5.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
    • 5.2.2. Germany
      • 5.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.3. France
      • 5.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.4. Italy
      • 5.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.5. United Kingdom
      • 5.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.6. Spain
      • 5.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
  • 5.3. Japan
    • 5.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
    • 5.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
    • 5.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence

6. Current Treatment Practices

  • 6.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
  • 6.2. Patient Journey

7. Unmet Needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis
  • Table 2: The GAP (Gender, Age, and Physiology) score
  • Table 3: The GAP index and staging system
  • Table 4: High resolution computed tomography criteria for up pattern
  • Table 5: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 6: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 7: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 8: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 9: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 10: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 11: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 12: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 13: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 14: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 15: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 16: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 17: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 18: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 19: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 20: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 21: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 22: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 23: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 24: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 25: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 26: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 27: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 28: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 29: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 30: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 31: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 32: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 33: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 34: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030

List of Figures

  • Figure 1: Risk factors associated with IPF
  • Figure 2: IPF associated clubbing of the fingertips
  • Figure 3: Stages of the pathogenesis of IPF
  • Figure 4: A schematic representing the current model for the pathogenesis of IPF
  • Figure 5: Possible mechanisms of fibrogenesis in IPF
  • Figure 6: Chest radiograph of a patient with IPF showing bilateral lower lobe reticular opacities (red circles)
  • Figure 7: Subpleural honeycombing in IPF diagnosed patients
  • Figure 8: ATS/ERS criteria for the diagnosis of idiopathic pulmonary fibrosis in the absence of surgical lung biopsy (2000).
  • Figure 9: Combination of high-resolution computed tomography and surgical lung biopsy for the diagnosis of IPF (requires multidisciplinary discussion)
  • Figure 10: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF
  • Figure 11: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 12: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 13: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 14: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 15: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 16: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 17: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 18: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 19: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 20: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 21: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 22: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 23: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 24: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 25: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 26: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 27: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 28: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 29: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 30: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 31: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 32: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 33: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 34: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 35: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 36: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 37: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 38: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 39: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 40: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 41: Suggested Algorithm for IPF Treatment
  • Figure 42: Unmet Needs of IPF